CTLA4 and metastatic melanoma: Ipilimumab has been shown to enhance pre-exisiting immune responses, including antitumor responses, by directly blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4) mediated T cell inhibition [1], [2] and is now FDA and EMA approved as treatment modality in patients with metastatic melanoma.